Method for the treatment of nephritis using anti-pdgf-dd antibodies
CA 2499207 A1 · Owner: Abgenix, Inc. · Inventors: Floege, Juergen; Lichenstein, Henri; Larochelle, William J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Embodiments of the invention described herein relate to antibodies directed to platelet derived growth factor-DD (PDGF-DD) and uses of such antibodies. The antibodies of the invention find use as diagnostics and as treatments for diseases associated with the overproduction of PDGF-DD. In particular in , accordance with embodiments of the invention the use of anti-PDGF-DD , antibodies for the treatment of nephritis and related disorders including , diseases caused by mesangial proliferation is provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 16, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 16, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 16, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.